This CME/CE activity will provide clinicians with an overview of the novel treatment strategies and management techniques for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The three expert faculty will review the pathophysiology of AML and ALL, including the methods used for diagnosing disease and monitoring treatment. An analysis of the latest data for current and emerging therapeutics will be discussed. The faculty will also review how to optimally utilize the healthcare team in developing treatment strategies to improve the quality of life for patients with AML or ALL. Upon completion of this educational activity, healthcare providers will gain insight in how to better treat and manage patients with AML and ALL to improve outcomes and quality of life.
Hematologists, oncologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with AML or ALL
- Understand the pathophysiology of AML and ALL, and the methods used to diagnose disease and monitor treatment
- Analyze the latest data for current and emerging therapeutics for the treatment of AML and ALL
- Utilize the healthcare team in developing treatment strategies to improve the quality of life and outcomes in patients with AML or ALL
Eytan M. Stein, MD (Course Chair)
Memorial Sloan Kettering Cancer Center
New York, New York
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
Eytan M. Stein, MD
|Consultant/Advisor: Agios, Inc.; Astellas Pharma US, Inc.; Auron Therapeutics; Celgene Corporation; Daiichi-Sankyo Company, Limited; Genentech, Inc.; PTC Therapeutics; Syros Pharmaceuticals, Inc.|
Bernadette M. Cuello, NP-AOCNP
|Nothing to disclose.|
Jae Park, MD
|Consultant/Advisor: Amgen Inc.; Allogene Therapeutics; AstraZeneca; Autolus; Incyte Corporation; Kite Pharma; Novartis AG; Takeda Pharmaceutical Company Limited|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this live material for a maximum of 1.0 CNE contact hour, including 1.0 pharmacotherapeutic contact hour (Provider number P0491).
This activity has been supported by an independent educational grant from Amgen Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].